Trifluoromethylphenyl is a key ingredient that contributes to the bioactivity of a number of clinical medications, including nilotinib (a tyrosine kinase inhibitor with antineoplastic activity), fluoxetine (an anti-depressant, anti-obsessional, anti-anxiety, and immune-modulating agent), and sorafenib (an RAF/MEK/ERK inhibitor with antineoplastic activity). The gene discussed is MAP2K7; the disease is Anxiety.